FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 469 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them September 10, 2021 Foodie Fridays: Apple Bok Choy Salad September 17, 2021 Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab... April 22, 2024 The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce September 27, 2018 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel No Survival Advantage from Radical Hysterectomy in Patients with Cervical Cancer... Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients...
